Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1968 2
1970 1
1972 1
1974 1
1975 2
1976 2
1977 5
1978 7
1979 8
1980 7
1981 3
1982 6
1983 6
1984 8
1985 4
1986 17
1987 14
1988 10
1989 11
1990 9
1991 9
1992 10
1993 7
1994 6
1995 7
1996 6
1997 15
1998 9
1999 15
2000 6
2001 8
2002 7
2003 15
2004 9
2005 14
2006 10
2007 14
2008 8
2009 15
2010 18
2011 14
2012 14
2013 13
2014 13
2015 21
2016 11
2017 8
2018 19
2019 18
2020 35
2021 23
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

495 results
Results by year
Filters applied: . Clear all
Page 1
Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T. Yamaoka T, et al. Among authors: kusumoto s. Int J Mol Sci. 2018 Nov 6;19(11):3491. doi: 10.3390/ijms19113491. Int J Mol Sci. 2018. PMID: 30404198 Free PMC article. Review.
Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.
Ohmori T, Yamaoka T, Ando K, Kusumoto S, Kishino Y, Manabe R, Sagara H. Ohmori T, et al. Among authors: kusumoto s. Int J Mol Sci. 2021 Jan 14;22(2):792. doi: 10.3390/ijms22020792. Int J Mol Sci. 2021. PMID: 33466795 Free PMC article. Review.
Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis.
Ando K, Akimoto K, Sato H, Manabe R, Kishino Y, Homma T, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Sagara H. Ando K, et al. Among authors: kusumoto s. Cancers (Basel). 2020 Apr 10;12(4):942. doi: 10.3390/cancers12040942. Cancers (Basel). 2020. PMID: 32290309 Free PMC article. Review.
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.
Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, Masaki Y, Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T. Shimada K, et al. Among authors: kusumoto s. Lancet Oncol. 2020 Apr;21(4):593-602. doi: 10.1016/S1470-2045(20)30059-0. Epub 2020 Mar 11. Lancet Oncol. 2020. PMID: 32171071 Clinical Trial.
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Kusumoto S, et al. Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19. Blood. 2019. PMID: 30341058 Free PMC article. Clinical Trial.
The Retro-Hydroformylation Reaction.
Kusumoto S, Tatsuki T, Nozaki K. Kusumoto S, et al. Angew Chem Int Ed Engl. 2015 Jul 13;54(29):8458-61. doi: 10.1002/anie.201503620. Epub 2015 Jun 18. Angew Chem Int Ed Engl. 2015. PMID: 26089259
495 results